As the Spring Equinox marks the start of a new year, 2025 witnessed a quiet yet pivotal shift in China’s innovative pharmaceutical sector. With the industry’s hype fading, the focus has converged on a core question: how to generate denser, more reliable clinical evidence – a priority that outweighs chasing fleeting technological trends.

As a key player in the clinical research ecosystem, UnionClin spent 2025 demonstrating its professional value in an era of uncertainty, delivering tangible progress across cutting-edge therapeutic areas including cell therapy, nucleic acid drugs, antibody-drug conjugates (ADCs), and radiopharmaceuticals.

Notable milestones include supporting the approval of Yuanyuanrui^® – a breakthrough cell therapy for lymphoma – through its Independent Central Imaging Review (IRC) services, and driving a first-in-class dual-target gene therapy for Parkinson’s disease to receive Fast Track Designation from the U.S. FDA in June 2025. UnionClin also provided end-to-end Phase I support for a first-in-class chronic hepatitis B cell therapy, advanced a novel solid tumor drug with innovative delivery technology into clinical trials, and led Phase II studies for refractory tumor-targeting ADCs and Phase II-III pivotal trials for a novel COPD biologic using advanced nano bispecific antibody technology.

To advance industry knowledge, UnionClin hosted 12 online webinars, co-organized salons with leading clinicians, and participated in key industry forums (VBEF, CBI, Antibody R&D Intelligence Summit) to discuss trends in cell and gene therapy (CGT), nucleic acid drugs, and intelligent antibody development. Its “UnionClin Insights” column also delivered practical, actionable perspectives from cross-functional experts.

The year brought well-deserved recognition: UnionClin was certified as an “internationally capable CRO” by the Shanghai Science and Technology Commission, ranked on Arterial Network’s “2025 Future Medical Top 100” list, and won awards for “Best Customer Satisfaction Pharmaceutical CRO” and “Outstanding Innovation Case in Innovative Drugs and Supply Chain 2025”. A successful Series B financing further strengthened its capacity for resource expansion and efficiency improvement.

Looking ahead, UnionClin remains focused on oncology, autoimmune diseases, and neuroscience – areas with significant unmet medical needs – while enhancing its capabilities in Phase II-III pivotal clinical trials. Leveraging its end-to-end services, deep clinical resources, and AI-powered digital platform, UnionClin is committed to addressing quality and efficiency challenges in drug development, serving as a trusted partner for innovative pharmaceutical companies.

In 2025, the industry redefined reliable growth – and UnionClin’s choice was to return to the fundamentals of clinical research, strengthening its expertise in evidence generation. The company believes that solid, trustworthy performance is the most reliable path through industry cycles, as it embarks on a new chapter with all industry partners.

About UnionClin

Founded in 2017 and headquartered in Shanghai, UnionClin is a specialized contract research organization (CRO) focused on clinical development for innovative drugs in oncology, autoimmune diseases, and neuroscience.

Backed by an AI-powered digital platform, professional clinical resources, and a highly experienced team, UnionClin has built an intelligent end-to-end service system covering the full lifecycle of drug development. From IND strategy to NDA filing, the company provides one-stop solutions for Phase I–III clinical trials.

Its comprehensive service offerings include: Medical Affairs, Clinical Operations, Data Management & Statistical Analysis, Clinical Pharmacology, Pharmacovigilance, Independent Central Imaging Review, Bioanalysis, Site Management Organization (SMO), and specialized professional staffing.

UnionClin possesses proven expertise in dual filings in China and the US, innovative trial design, and global multi-center clinical research services. The company is committed to introducing high-quality overseas assets while accelerating the internationalization of domestic innovative therapies.

With a team of more than 500 professionals, UnionClin operates in over 100 cities across China. It has established strong partnerships with more than 2,000 key opinion leaders (KOLs) and over 1,000 clinical research sites, and has supported more than 400 clinical development programs.